PMID- 34889733
OWN - NLM
STAT- MEDLINE
DCOM- 20220323
LR  - 20220323
IS  - 0946-1965 (Print)
IS  - 0946-1965 (Linking)
VI  - 60
IP  - 4
DP  - 2022 Apr
TI  - Comparative efficacy and safety of topiroxostat at different dosages in 
      hyperuricemic patients with or without gout: A network meta-analysis of 
      randomized controlled trials.
PG  - 176-183
LID - 10.5414/CP204108 [doi]
AB  - OBJECTIVE: We aimed to assess the relative efficacy and safety of topiroxostat at 
      different dosages in hyperuricemic patients with or without gout. MATERIALS AND 
      METHODS: A Bayesian network meta-analysis was performed to combine direct and 
      indirect evidence from randomized controlled trials (RCTs) for evaluating the 
      efficacy and safety of topiroxostat at different dosages, allopurinol 200 mg, and 
      placebo in hyperuricemic patients with or without gout. RESULTS: Five RCTs, 
      including 733 patients, fulfilled the inclusion criteria. The number of patients 
      who had achieved a target serum uric acid (sUA) level was significantly higher in 
      the topiroxostat 200 mg group than in the placebo group (odds ratio, 1,023; 95% 
      credible interval, 157.7 - 26,260). Similarly, the number of patients who had 
      achieved the target sUA level was significantly higher with topiroxostat at other 
      dosages and allopurinol than with placebo. The ranking probability based on the 
      surface under the cumulative ranking curve indicated that topiroxostat 200 mg was 
      more likely to achieve the best target sUA level, followed by topiroxostat 80 mg, 
      allopurinol 200 mg, topiroxostat 120 mg, topiroxostat 160 mg, topiroxostat 60 mg, 
      topiroxostat 40 mg, and placebo. The frequency of adverse events (AEs) in the 
      placebo group was lower than that in the topiroxostat 40 mg, topiroxostat 60 mg, 
      and topiroxostat 200 mg groups. CONCLUSION: Topiroxostat 200 mg was the most 
      effective treatment option for hyperuricemic patients with or without gout, with 
      an increased risk of AEs.
FAU - Lee, Young Ho
AU  - Lee YH
FAU - Song, Gwan Gyu
AU  - Song GG
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PL  - Germany
TA  - Int J Clin Pharmacol Ther
JT  - International journal of clinical pharmacology and therapeutics
JID - 9423309
RN  - 0 (Gout Suppressants)
RN  - 0 (Nitriles)
RN  - 0 (Pyridines)
RN  - 0J877412JV (FYX-051)
RN  - 268B43MJ25 (Uric Acid)
SB  - IM
MH  - *Gout/diagnosis/drug therapy
MH  - *Gout Suppressants/adverse effects
MH  - Humans
MH  - Network Meta-Analysis
MH  - Nitriles
MH  - Pyridines
MH  - Randomized Controlled Trials as Topic
MH  - Treatment Outcome
MH  - Uric Acid
EDAT- 2021/12/11 06:00
MHDA- 2022/03/24 06:00
CRDT- 2021/12/10 12:15
PHST- 2022/03/10 00:00 [accepted]
PHST- 2021/12/11 06:00 [pubmed]
PHST- 2022/03/24 06:00 [medline]
PHST- 2021/12/10 12:15 [entrez]
AID - 188999 [pii]
AID - 10.5414/CP204108 [doi]
PST - ppublish
SO  - Int J Clin Pharmacol Ther. 2022 Apr;60(4):176-183. doi: 10.5414/CP204108.